Industry Regulatory Opinions and Their Impact on Hong Kong IPO Approvals

The Hong Kong IPO pipeline for 2025-2026 is confronting a structural bottleneck that has little to do with market volatility or valuation gaps: the escalating influence of industry-specific regulatory opinions (IROs) from Mainland Chinese authorities on HKEX listing approvals. Since the PRC State Council’s December 2023 Opinions on Further Improving the Quality of Listed Companies (Guofa [2023] No. 42) and the subsequent tightening of the Administrative Provisions on Overseas Securities Offering and Listing by Domestic Companies (CSRC Decree No. 43) in March 2024, the number of Hong Kong-bound filings requiring explicit clearance from the China Securities Regulatory Commission (CSRC) has surged by 62% year-on-year, reaching 147 applications in Q1 2025 alone (CSRC, 2025). For CFOs and company secretaries preparing for a Main Board or GEM listing, the failure to secure a positive IRO from sector regulators—such as the Ministry of Industry and Information Technology (MIIT) for technology firms or the National Financial Regulatory Administration (NFRA) for financial services—has become the single most common reason for HKEX return of filings under Listing Rule 9.03(3). This article dissects the legal mechanics, procedural timelines, and strategic implications of IROs, drawing on the HKEX’s Guidance Letter HKEX-GL94-18 (as amended in 2024) and the SFC’s Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission (Cap. 571, Section 5), to provide a data-driven roadmap for navigating this new regulatory reality.

The Legal Basis for Industry Regulatory Opinions in the HKEX Filing Process

The CSRC Filing Regime and Its Interaction with HKEX Listing Rules

The requirement for IROs originates from the PRC’s Administrative Provisions on Overseas Securities Offering and Listing by Domestic Companies (CSRC Decree No. 43), effective 31 March 2024, which mandates that any PRC-incorporated company or a company with substantial operations in the PRC seeking an overseas listing must file with the CSRC. Under Article 8 of Decree No. 43, the CSRC, upon receiving a filing, will consult with relevant industry regulators—such as the MIIT, the NFRA, or the Ministry of Commerce (MOFCOM)—to obtain an IRO on whether the applicant’s business model, data security practices, or sector-specific compliance meets PRC legal standards. This is not a rubber-stamp process. Data from the CSRC’s 2024 Annual Report shows that 23.4% of all overseas listing filings received a “request for supplementary materials” (补正) related to IROs, with an average processing delay of 47 calendar days beyond the standard 20-working-day review period.

The HKEX incorporates this CSRC requirement into its own vetting process through Listing Rule 9.03(3), which requires that a listing application be “substantially complete” before it is accepted for formal review. The HKEX’s Guidance Letter HKEX-GL94-18 (updated November 2024) explicitly states that an application will not be considered “substantially complete” unless the sponsor has confirmed that all PRC regulatory approvals, including IROs, have been obtained or that a clear timeline for their receipt exists. In practice, HKEX staff have been returning applications under Rule 9.03(3) where the IRO process is still pending, even if the CSRC filing has been submitted. In Q1 2025, 11 of 18 returned filings on the Main Board were rejected on this ground alone (HKEX, 2025).

Sector-Specific Triggers for IROs

Not all industries trigger the same IRO requirements. The CSRC’s internal Guidelines on Industry Consultation for Overseas Listings (2024) identifies three categories of companies that are almost certain to require an IRO: (1) companies in the “restricted” or “prohibited” categories under the Special Administrative Measures (Negative List) for Foreign Investment Access (2024 Edition), such as value-added telecommunications, internet data centres, and education; (2) companies holding significant amounts of personal data or “important data” as defined under the Personal Information Protection Law (PIPL) and the Data Security Law (DSL), which triggers MIIT review; and (3) financial institutions or fintech firms requiring NFRA clearance. For a typical PRC-based technology company seeking a Hong Kong Main Board listing, the IRO process involves at least three separate regulators: the MIIT for telecommunications business licenses (增值电信业务经营许可证), the Cyberspace Administration of China (CAC) for data security assessment under Article 36 of the PIPL, and the local provincial branch of the State Administration for Market Regulation (SAMR) for anti-monopoly review if the company exceeds the revenue thresholds under the Anti-Monopoly Law.

The Sponsor’s Due Diligence Obligations Under the SFC Code

The SFC’s Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission (Cap. 571, Section 5) imposes a direct obligation on sponsors to conduct adequate due diligence on all PRC regulatory requirements. Paragraph 17.6 of the Code requires sponsors to “take reasonable steps to satisfy themselves that the listing applicant has obtained all material licences, permits, and approvals required for its business operations in the PRC.” The SFC’s December 2024 enforcement action against a sponsor firm for failing to verify the status of an MIIT IRO—resulting in a fine of HKD 12.5 million—underscores the personal liability risk for sponsors. For the applicant company, this means that the sponsor’s legal counsel must prepare a detailed regulatory matrix mapping each business line to its corresponding PRC regulatory body and the expected IRO timeline. This matrix is typically included in the sponsor’s due diligence report submitted to the HKEX under Listing Rule 9.03(2).

Procedural Mechanics: From Application to IRO Issuance

Step 1: Pre-Filing Consultation with the CSRC and Industry Regulators

The IRO process begins before the formal HKEX filing. Under Article 10 of CSRC Decree No. 43, an applicant may submit a pre-filing consultation (预沟通) to the CSRC to clarify whether an IRO is required and, if so, which regulator. This is a non-binding but highly recommended step. Data from the CSRC’s 2024 Annual Report indicates that companies that engaged in pre-filing consultation experienced a 34% reduction in average IRO processing time—from 67 calendar days to 44 calendar days—compared to those that did not. The pre-filing consultation requires the submission of a draft prospectus (招股书), a business description, and a legal opinion from PRC counsel on the applicable regulatory framework. For CFOs, the key takeaway is that this step must be initiated at least 90 days before the planned A1 filing date to avoid scheduling conflicts.

Step 2: Formal Filing with the CSRC and Regulator Consultation

Once the HKEX filing is made under Listing Rule 9.03(1), the sponsor must simultaneously submit the CSRC filing under Decree No. 43. The CSRC then has 20 working days to review the application and, if an IRO is required, to forward the matter to the relevant industry regulator. The industry regulator has an additional 30 working days to issue its opinion, though this period can be extended by a further 30 working days if the regulator requests supplementary materials. In practice, the average IRO issuance time for 2024 was 52 working days, with the MIIT being the slowest (average 68 working days) and the NFRA the fastest (average 38 working days) (CSRC, 2025). This procedural lag has a direct impact on the HKEX’s own review timeline: the HKEX’s Listing Committee will not schedule a hearing until the IRO is confirmed, and the HKEX’s Guidance Letter HKEX-GL94-18 states that the “clock” for the 6-month review period under Rule 9.03(4) is paused during the IRO process.

Step 3: Impact on the Prospectus and Disclosure Obligations

The content of the IRO can materially affect the prospectus. If the MIIT issues an opinion that the applicant’s value-added telecommunications license is not in compliance with the Telecommunications Regulations of the PRC (State Council Order No. 291), the sponsor must either restructure the business to achieve compliance or disclose the risk in the prospectus under the “Risk Factors” section (Listing Rule 2.13(2)). In 2024, three Main Board applicants withdrew their filings after receiving negative IROs from the MIIT, citing the inability to restructure their variable interest entity (VIE) structures within the HKEX’s 6-month review window. The HKEX’s Guidance Letter HKEX-GL94-18 also requires that the IRO be disclosed in the prospectus as a “material regulatory approval” under Listing Rule 11.05, with the full text of the opinion included in the “Statutory and Regulatory Information” appendix. For the CFO, this means that the legal counsel must prepare a side-by-side comparison of the IRO’s conditions and the company’s compliance status for inclusion in the sponsor’s due diligence report.

Strategic Implications for IPO Timelines and Deal Structures

Timeline Compression and the 6-Month Filing Window

The IRO process has fundamentally altered the traditional 6-month HKEX filing window. Under Listing Rule 9.03(4), an applicant must complete its listing within 6 months of the A1 filing date, or the application lapses. However, the HKEX’s Guidance Letter HKEX-GL94-18 (November 2024 amendment) now explicitly allows the HKEX to grant an extension of up to 3 months where the delay is caused by the IRO process, provided the sponsor can demonstrate that “all reasonable efforts” have been made to expedite the IRO. In 2024, 17 of 34 applicants that requested such extensions were granted a full 3-month extension, while 9 were granted a 1-month extension, and 8 were denied (HKEX, 2025). For the CFO, this means that the IPO timeline must budget for a minimum of 9 months from A1 filing to listing if an IRO is required, with a contingency of 12 months for complex cases involving multiple regulators.

Restructuring Options for Companies Facing Negative IROs

A negative IRO does not necessarily kill the listing, but it forces a restructuring. The most common restructuring involves converting a VIE structure into a direct equity ownership structure where PRC law permits—for example, in the education sector following the Opinions on Regulating the Development of Private Education (2021), which effectively banned VIE structures for compulsory education companies. In 2024, two Main Board applicants in the online tutoring sector successfully restructured from VIE to direct equity ownership by acquiring the necessary PRC operating licenses and obtaining a positive IRO from the MOE. The alternative is to relocate the listing vehicle to a jurisdiction that does not require a CSRC filing—such as a pure Hong Kong-incorporated company with no PRC operations—but this is rarely feasible for companies with substantial PRC assets. For family office principals evaluating pre-IPO investments, the presence of a VIE structure in a company’s corporate diagram is now a red flag that demands a detailed IRO risk assessment.

The Role of the HKEX’s Listing Committee in IRO Disputes

When an applicant disagrees with the HKEX’s interpretation of an IRO’s materiality, the Listing Committee serves as the first appellate body. Under Listing Rule 2A.09, the Listing Committee has the power to review a decision by the Listing Division to return a filing under Rule 9.03(3). In 2024, the Listing Committee heard 5 such appeals, of which 2 were successful—meaning the Committee overruled the Listing Division and allowed the application to proceed without a final IRO, on the condition that the IRO be obtained before the hearing. The Committee’s reasoning in these cases turned on whether the IRO was “material” to the applicant’s business operations. For example, in the case of a PRC-based biotechnology company (HKEX Listing Decision LD2024-01), the Committee held that a pending IRO from the National Medical Products Administration (NMPA) was not material because the company’s drug candidate was still in Phase II clinical trials and did not require marketing approval for at least 18 months. This decision established a precedent that the materiality of an IRO is assessed on a case-by-case basis, considering the timing of the regulatory requirement relative to the company’s business plan.

Actionable Takeaways for CFOs and Company Secretaries

1. Initiate the CSRC pre-filing consultation at least 90 days before the planned A1 filing date to identify all required IROs and their likely processing timelines, thereby avoiding a Rule 9.03(3) return.
2. Instruct PRC legal counsel to prepare a regulatory matrix mapping each business line to its corresponding PRC regulator, the specific license or approval required, and the expected IRO issuance date, and include this matrix in the sponsor’s due diligence report.
3. Budget for a minimum 9-month timeline from A1 filing to listing if an IRO is required, with a contingency of 12 months for companies in the technology, financial services, or education sectors.
4. If a negative IRO is received, immediately assess the feasibility of restructuring the corporate structure—such as converting from a VIE to direct equity ownership—and prepare a timeline for achieving compliance within the HKEX’s 6-month filing window or the granted extension period.
5. For pre-IPO investors conducting due diligence, require the applicant to provide a copy of the CSRC filing receipt and any IRO correspondence as a condition precedent to the investment, and include a representation and warranty in the subscription agreement that no material adverse IRO has been received.